Company news_innoModel-Provide preclinical pharmacological services

Cn /En

News Center

——

Company news

Industry news

01-12

InnoModels Biotechnology: Innovations in CAR-NK Cell Therapy

As part of its ongoing commitment to push the frontiers of science in the biomedical field, the latest innovation from InnoModels Biotechnology is the introduction of CAR-NK (Chimeric Antigen Receptor Natural Killer) cell therapy in the field of immunotherapy. This innovative treatment is expected to demonstrate unprecedented efficacy in the treatment of cancer and other immune-related diseases

01-12

InnoModels Biotechnology: Breakthrough in Host Versus Graft (HVG) Research

InnoModels Biotechnology is committed to research and innovation in the life sciences and has recently made an impressive breakthrough in the field of host-versus-graft (HVG) response. This achievement will open up new possibilities in areas such as organ transplantation and immunotherapy, and is expected to solve problems such as transplant rejection.

01-12

InnoModels Biotechnology: Introduction to the In Vitro Killing Platform

InnoModels Biotechnology has always been committed to driving innovation in the life sciences, and its in vitro killing platform is one of the company's major achievements in life sciences research and drug discovery. The platform provides researchers with a highly controllable and precise experimental environment, enabling in vitro cell killing experiments to be conducted more efficiently and reliably, and providing powerful support for new drug screening and drug mechanism research.

01-11

InnoModels Biotechnology: PDC High-Throughput In Vitro Drug Discovery

InnoModels Biotechnology is committed to driving technological innovation in the life sciences, and its PDC (Phenotypic Drug Discovery) high-throughput in vitro efficacy technology plays an important role in drug discovery, not only providing highly reduced biological models, but also accelerating the process of drug screening and evaluation, enabling researchers to find promising drug candidates faster and more accurately. PDC technology not only provides highly reductive biological models, but also accelerates the process of drug screening and evaluation, enabling researchers to find potential drug candidates more quickly and accurately

< 1...54 55 56...61 >

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL: +86 15711355061
E-mail: xuyl@imodels.tech
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

InnoModels Biotechnology (Beijing) Co., Ltd

SEO

Business License